Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig
Changhai Lei, Wenyan Fu, Kewen Qian, Tian Li, Sheng Zhang, Min Ding, Shi Hu
doi: https://doi.org/10.1101/2020.02.01.929976
This article is a preprint and has not been certified by peer review [what does this mean?].
Abstract
A novel coronavirus, designated as 2019-nCoV, emerged in Wuhan, China, at the end of 2019. As of Feb 1, 2020, at least 11,844 cases had been diagnosed in China, however, there is no specific antiviral treatment or vaccine currently. Very recently report have suggest that novel CoV uses the same cell entry receptor, ACE2, as SARS-CoV. In this report, we generated a new recombinant protein by connecting the extracellular domain of human ACE2 to the Fc region of the human immunoglobulin IgG1. An ACE2 mutant with low catalytic activity was also used in the study. The fusion proteins were then characterized. Both fusion proteins has high affinity binding to the receptor-binding domain (RBD) of SARS-CoV and 2019-nCoV and exerted desired pharmacological properties. Moreover, fusion proteins potently neutralized SARS-CoV and 2019-nCoV in vitro. As these fusion proteins exhibit cross-reactivity against coronavirus and could have potential applications for diagnosis, prophylaxis, and treatment of 2019-nCoV.
*注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
